Published in Cancer Res on March 15, 2008
Antigen-specific memory regulatory CD4+Foxp3+ T cells control memory responses to influenza virus infection. J Immunol (2013) 1.16
Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells. J Immunother (2010) 1.06
Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma. J Clin Invest (2011) 1.03
Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients. Cancer Immunol Immunother (2013) 0.94
Protective CD8 memory T cell responses to mouse melanoma are generated in the absence of CD4 T cell help. PLoS One (2011) 0.93
Immunomodulatory cytokines as therapeutic agents for melanoma. Immunotherapy (2011) 0.88
Targeting a mimotope vaccine to activating Fcgamma receptors empowers dendritic cells to prime specific CD8+ T cell responses in tumor-bearing mice. J Immunol (2009) 0.84
Characterization of surgical models of postoperative tumor recurrence for preclinical adjuvant therapy assessment. Am J Transl Res (2012) 0.83
Induction of antitumor immunity ex vivo using dendritic cells transduced with fowl pox vector expressing MUC1, CEA, and a triad of costimulatory molecules (rF-PANVAC). J Immunother (2012) 0.76
Forced co-expression of IL-21 and IL-7 in whole-cell cancer vaccines promotes antitumor immunity. Sci Rep (2016) 0.75
Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol (2004) 17.54
Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst (1957) 10.10
Defective CD8 T cell memory following acute infection without CD4 T cell help. Science (2003) 9.67
Memory CD8 T-cell differentiation during viral infection. J Virol (2004) 6.75
Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest (2005) 5.30
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A (2005) 5.21
Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med (2004) 4.77
CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev (2006) 4.49
CD25+CD4+ T cells contribute to the control of memory CD8+ T cells. Proc Natl Acad Sci U S A (2002) 2.44
Regulatory T cells and cancer. Curr Opin Immunol (2007) 2.41
Maintenance, loss, and resurgence of T cell responses during acute, protracted, and chronic viral infections. J Immunol (2004) 2.28
Changing immunodominance patterns in antiviral CD8 T-cell responses after loss of epitope presentation or chronic antigenic stimulation. Virology (2003) 1.69
Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J Exp Med (2003) 1.68
Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol (2006) 1.64
Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer Res (2006) 1.57
Gammaherpesvirus persistence alters key CD8 T-cell memory characteristics and enhances antiviral protection. J Virol (2006) 1.36
Induction of postsurgical tumor immunity and T-cell memory by a poorly immunogenic tumor. Cancer Res (2007) 1.24
Immunological consequences of tumor excision: from active immunity to immunological memory. Int J Cancer (1986) 0.96
A DNA vaccine targeting Fos-related antigen 1 enhanced by IL-18 induces long-lived T-cell memory against tumor recurrence. Cancer Res (2005) 0.93
Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem (2005) 4.65
IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol (2010) 3.43
Activated primary and memory CD8 T cells migrate to nonlymphoid tissues regardless of site of activation or tissue of origin. J Immunol (2004) 3.15
CD4+ T cell regulation of CD25 expression controls development of short-lived effector CD8+ T cells in primary and secondary responses. Proc Natl Acad Sci U S A (2009) 2.01
Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. J Clin Invest (2006) 1.59
Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Adv Drug Deliv Rev (2004) 1.58
Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer Res (2006) 1.57
Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. Blood (2008) 1.43
Gammaherpesvirus persistence alters key CD8 T-cell memory characteristics and enhances antiviral protection. J Virol (2006) 1.36
Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor-mediated drug delivery. Mol Pharmacol (2004) 1.35
Recall responses by helpless memory CD8+ T cells are restricted by the up-regulation of PD-1. J Immunol (2009) 1.34
IL-15-independent proliferative renewal of memory CD8+ T cells in latent gammaherpesvirus infection. J Immunol (2004) 1.30
Different functional capacities of latent and lytic antigen-specific CD8 T cells in murine gammaherpesvirus infection. J Immunol (2004) 1.30
Programmed death 1 regulates development of central memory CD8 T cells after acute viral infection. J Immunol (2011) 1.29
Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression. Mol Immunol (2008) 1.27
Induction of postsurgical tumor immunity and T-cell memory by a poorly immunogenic tumor. Cancer Res (2007) 1.24
Control of memory CD8+ T cell differentiation by CD80/CD86-CD28 costimulation and restoration by IL-2 during the recall response. J Immunol (2008) 1.22
Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo. Adv Immunol (2006) 1.21
Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity. Oncogene (2003) 1.16
Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge. J Immunol (2012) 1.16
New perspectives on the role of vitiligo in immune responses to melanoma. Oncotarget (2011) 1.15
Murid herpesvirus 4 strain 68 M2 protein is a B-cell-associated antigen important for latency but not lymphocytosis. J Virol (2003) 1.14
CD80 and CD86 control antiviral CD8+ T-cell function and immune surveillance of murine gammaherpesvirus 68. J Virol (2006) 1.11
A retinoic acid--rich tumor microenvironment provides clonal survival cues for tumor-specific CD8(+) T cells. Cancer Res (2012) 1.09
Immunity to cancer through immune recognition of altered self: studies with melanoma. Adv Cancer Res (2003) 1.07
Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains. Clin Cancer Res (2006) 1.04
Cutting edge: IL-2 immune complexes as a therapy for persistent virus infection. J Immunol (2009) 1.04
Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma. J Clin Invest (2011) 1.03
Suppressive CD8+ T cells arise in the absence of CD4 help and compromise control of persistent virus. J Immunol (2011) 1.02
CD8+ T cell dysfunction and increase in murine gammaherpesvirus latent viral burden in the absence of 4-1BB ligand. J Immunol (2007) 1.01
Immune responses against persistent viral infections: possible avenues for immunotherapeutic interventions. Crit Rev Immunol (2008) 0.99
Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens. J Immunol (2010) 0.96
MicroRNA miR-155 affects antiviral effector and effector Memory CD8 T cell differentiation. J Virol (2012) 0.93
Protective CD8 memory T cell responses to mouse melanoma are generated in the absence of CD4 T cell help. PLoS One (2011) 0.93
Strain-dependent requirement for IFN-γ for respiratory control and immunotherapy in murine gammaherpesvirus infection. Viral Immunol (2011) 0.90
Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma. Cancer Lett (2009) 0.89
Critical role for all-trans retinoic acid for optimal effector and effector memory CD8 T cell differentiation. J Immunol (2013) 0.88
Murine gammaherpesvirus 68 LANA acts on terminal repeat DNA to mediate episome persistence. J Virol (2012) 0.87
GM-CSF DNA induces specific patterns of cytokines and chemokines in the skin: implications for DNA vaccines. Cytokines Cell Mol Ther (2002) 0.87
Adenocarcinoma contains more immune tolerance regulatory t-cell lymphocytes (versus squamous carcinoma) in non-small-cell lung cancer. Lung (2013) 0.86
Multiple murine BRaf(V600E) melanoma cell lines with sensitivity to PLX4032. Pigment Cell Melanoma Res (2014) 0.85
Immune escape of γ-herpesviruses from adaptive immunity. Rev Med Virol (2014) 0.84
Phagocytes mediate targeting of iron oxide nanoparticles to tumors for cancer therapy. Integr Biol (Camb) (2013) 0.84
Differential requirements for CD80/86-CD28 costimulation in primary and memory CD4 T cell responses to vaccinia virus. Cell Immunol (2010) 0.80
Autoimmune vitiligo does not require the ongoing priming of naive CD8 T cells for disease progression or associated protection against melanoma. J Immunol (2014) 0.80
Regulatory CD8+ T cells associated with erosion of immune surveillance in persistent virus infection suppress in vitro and have a reversible proliferative defect. J Immunol (2013) 0.79
CD4 and CD8 T cells directly recognize murine gammaherpesvirus 68-immortalized cells and prevent tumor outgrowth. J Virol (2013) 0.79
Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recovery. J Clin Oncol (2010) 0.79
T-cell responses to the M3 immune evasion protein of murid gammaherpesvirus 68 are partially protective and induced with lytic antigen kinetics. J Virol (2004) 0.78
CD4(+) T-cell dependence of primary CD8(+) T-cell response against vaccinia virus depends upon route of infection and viral dose. Cell Mol Immunol (2014) 0.75